INFORMATION DISCLOSURE CITATION IN AN APPLICATION (PTO-1449)

ATTY. DOCKET NO. 114232.107	SERIAL NO. 09/518,098
APPLICANT Leland SHAPIRO	
FILING DATE May 3, 2000	GROUP 1653

U.S. PATENT DOCUMENTS

EXAMINER'S INITIALS		PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA	5,175,253	12/29/92	Fallon et al.			
	AB	5,214,191	5/25/93	Kirschenheuter et al			
	AC	5,240,956	8/31/93	Kirschenheuter et al			
	AD	5,281,617	1/25/94	Kirschenheuter et al			
	AE	5,314,910	5/24/94	Kirschenheuter et al			
	AF	5,416,191	5/16/95	Cheronis et al			
	AG	5,478,727	12/26/95	Roizman et al			
	AH	5,486,470	1/23/96	Darke et al			
	AI	5,514,653	5/7/96	Perlmutter			
	AJ	5,610,140	3/11/97	Goodfellow et al			
	AK	5,635,593	6/3/97	Cheronis et al			
	AL	5,663,416	9/2/97	Kirschenheuter et al			
	AM	5,700,779	12/23/97	Goodfellow et al			
	AN	5,710,026	1/20/98	Sprecher			
	AO	5,712,117	1/27/98	Sprecher			
	AP	5,747,645	6/6/98	Sprecher			
	AQ	5,750,506	5/12/98	Goodfellow et al			
	AR	5,759,548	6/2/98	Bathurst et al.			
	AS	5,798,442	8/25/98	Gallant et al.			
	AT	5,811,241	9/22/98	Goodfellow et al			
	AU	5,834,431	11/10/98	Stewart et al			
	AV	5,843,900	12/1/98	Cheronis et al			
	AW	5,849,863	12/15/98	Stewart et al			
	AX	5,863,899	1/26/99	Cheronis et al			
	AY	5,874,424	2/23/99	Batchelor et al.			

EXAMINER Not considered	DATE CONSIDERED 1

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

INFORMATION DISCLOSURE CITATION IN AN APPLICATION (PTO-1449)

ATTY. DOCKET NO.	SERIAL NO.
114232.107	09/518,098
APPLICANT: Leland SHAPIRO	
FILING DATE: May 3, 2000	GROUP

FOREIGN PATENT DOCUMENTS

EXAMINER'S INITIALS		PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	Translation Yes	Translation No
X	BA	~~WO 97/03679~~	~~2/6/97~~	~~PCT~~				
X	BB	~~WO98/09206~~	~~3/5/98~~	~~PCT~~			Abstr	
DL	BC	WO97/09346	3/13/97	PCT				
	BD	WO97/09347	3/13/97	PCT				
	BE	WO97/10222	3/20/97	PCT				
	BF	WO98/06417	2/29/98	PCT				
	BG	WO98/49190	11/5/98	PCT				
	BH	WO00/52034						
DL	BI	WO99/43308	9/2/99					
DL	BJ	WO94/07525		PCT				

EXAMINER	DATE CONSIDERED
David Lutton	12/9/03

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not inconformance and not considered. Include copy of this form with next communication to Applicant.

INFORMATION DISCLOSURE CITATION IN AN APPLICATION (PTO-1449)	ATTY. DOCKET NO. 114232.107	SERIAL NO. 09/518,098
	APPLICANT Leland SHAPIRO	
	FILING DATE May 3, 2000	GROUP 1653

		OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)
DL	CA	Adelman S.F. et al., "Protease inhibitors suppress fibrinolytic activity of herpesvirus-transformed cells", *J Gen Virol*, **1982**, *60(Pt 1)*:15-24.
DL	CB	Altieri, D.C. *J Leukoc Biol 1995, 58,* [illegible] 120 - 127
X	CC	~~*Animal Cell Culture*, R. I. Freshney~~, ed., 1986
DL	CD	Aoki H, Akaike T, Abe K, Kuroda M, Arai S, Okamura R, Negi A, Maeda H. *Antiviral effect of oryzacystatin, a proteinase inhibitor in rice, against herpes simplex virus type I in vitro and in vivo.* Antimicrob Agents Chemother 1995 Apr;39(4):846-9
	CE	Beal, M.F., "Mitochondria, Free Radicals, and Neurodegeneration", *Curr. Opin. Neurobiol.*, **1996,** 6, 661-666
	CF	Beck, K.F. et al. in *J Exp Biol 1999,* 202, [illegible] 645 - 653
	CG	Bjorck L, Grubb A, Kjellen L. Cystatin C, a human proteinase inhibitor, blocks replication of herpes simplex virus. J Virol 1990 Feb;64(2):941-3
DL	CH	Bratt J, Palmblad J. *Cytokine-induced neutrophil1 5 mediated injury of human endothelial cells. J Immunol* 1997 Jul 15; 159(2):812-8
X	CI	Bukrinskaia ~~AG, Kitsak Vla, Moisiadi SA~~, Arakelov SA. *Suppression of rotavirus SA-II reproduction by protease inhibitors in cell culture.* Vopr Virusol 1987 Jan-Feb;32(l):71-4
DL	CJ	Chesnokova NB, Maichuk YF. *Antiproteases in herpetic keratitis.* Metab Pediatr Syst Ophthalmol 1986;9(l):593-6
X	CK	~~Chesnokova NB, Kasavina BS, Maichuk IuF~~, Kazachenko MA, Shchipanova AI. *Main proteolytic inhibitors in ocular herpes.* Vopr Med Khim 1981 Sep-Oct;27(5):663-5
DL	CL	Cilberto et al., 1995, *Cell*, 41:531-540
	CM	Deigner, H.P. and R. Kinscherf, "Modulating Apoptosis: Current Applications and Prospects for Future Drug Development", Curr Med *Chem* **1999,** 6, 399-414
	CN	Dery, 0. and Bunnett, *N.W. Biochem Soc Trans 1999,* 2 7,246-254
	CO	Dery, 0. et al. *Am J Physiol 1998, 2 74,* C 1429-C 1452
DL	CP	DiIanni CL, Drier DA, Deckman IC, McCann PJ 3d, Liu F, Roizinan B, Colonno RJ, Cordingley MG. Identification of the herpes simplex virus-I protease cleavage sites by direct sequence analysis of autoproteolytic cleavage products. Biol Chem 1993 Jan 25;268(3):2048-51

EXAMINER	DATE CONSIDERED
David Lukton	12/4/01

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in onformance and not considered. Include copy of this form with next communication to Applicant.

INFORMATION DISCLOSURE CITATION IN AN APPLICATION (PTO-1449)	ATTY. DOCKET NO. 114232.107	SERIAL NO. 09/518,098
	APPLICANT Leland SHAPIRO	
	FILING DATE May 3, 2000	GROUP

		OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)
	CQ	Dilanni CL, Stevens JT, Bolgar M, O'Boyle DR 2nd, Weinheimer SP, Colonno RJ. Identification of the serine residue at the active site of the herpes simplex virus type 1 protease. J Biol Chem 1994 Apr 29;269(17):12672-6
	CR	Ding, A. et al., in J. *Immunol.* 1990, 145, 940
	CS	Estaquier J, Tanaka M, Suda T, Nagata S, Golstein P, Ameisen JC. Fas-mediated apoptosis of CD4+ and CD8+ T cells from human immunodeficiency virus-infected persons: differential in vitro preventive effect of cytokines and protease antagonists. Blood 1996 Jun 15;87(12):4959-66
	CT	Flaitz CM, Hicks MJ. "Molecular piracy: the viral link to carcinogenesis." *Oral Oncol* 1998 Nov;34(6):448-53
	CU	Glynn JM, McElligott DL, Mosier DE. Apoptosis induced by HIV 5 infection in H9 T cells is blocked by ICE-family protease inhibition but not by a Fas(CD95) antagonist. J Immunol 1996 Oct 1;157(7):2754-2758
	CV	Goureau, 0. et al., in *Proc. Natl. Acad. Sci. U.S.A.* 1993, 90, 4276
	CW	Griffin, William C. , "Calculation of HLB Values of Non-Ionic Sufactants", [H. L. B. - The Hydrophilic-Lipophilic Balance], J. Soc. Cos. Met. Chem., Vol. 5, p. 249 (1954)
	CX	Heck, D. E. et al., in *J. Biol. Chem.* 1990, 267, 21277
	CY	Holwerda BC. Herpesvirus proteases: targets for novel antiviral drugs. Antiviral Res 1997 Jun;35(l):1-21
	CZ	Jabs, Thorsten, "Reactive Oxygen Intermediates as Mediators of Programmed Cell Death in Plants and Animals", *Biochem Pharmacol* **1999** 57, 231-245
	CCA	Kaufmann, Scott H., Serge Desnoyers, Yvonne Ottaviano, Nancy E. Davidson, and Guy G. Poirier, "Specific Proteolytic Cleavage of Poly(ADP-ribose) Polymerase: An Early Marker of Chemotherapy-induced Apoptosis", *Cancer Res* **1993,** *53,* 3976
	CCB	Kidd, Vincent J., PROTEOLYTIC ACTIVITIES THAT MEDIATE APOPTOSIS, *Annu Rev Physiol,* 1998, 60, 533
	CCC	Kido H, Niwa Y, Beppu Y, Towatari T. *Cellular proteases involved in the pathogenicity of enveloped animal viruses, human immunodeficiency virus, influenza virus A and Sendai virus. Adv Enzyme Regul* 1996;36:325-47
	CCD	Kirkeboen, K.A. and Strand, O.A. in *Acta Anaesthesiol Scand 1999, 43,* 275
	CCE	Langer, R. *Nature* 1998, *392, 5*
	CCF	List, P.J.M., et al., *Arterioscler Thromb Vasc Biol* **1999,** 19, 14

EXAMINER David Peter	DATE CONSIDERED 12/1/01

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

INFORMATION DISCLOSURE CITATION IN AN APPLICATION (PTO-1449)	ATTY. DOCKET NO. 114232.107	SERIAL NO. 09/518,098
	APPLICANT Leland SHAPIRO	
	FILING DATE May 3, 2000	GROUP 1653

		OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)
	CCG	Lomas DA, Elliott PR, Carrell RW. *Commercial plasma alphal-antitrypsin (Prolastin) contains a confornationally inactive, latent component.* Eur Respir J 1997 Mar;10(3):672-5
	CCH	Lowenstein, C. J. and Snyder, S.H. in *Cell* 1992, 70, 705-707
	CCI	Lowenstein C. J. et al. *in Proc. Natl. Acad. Sci. USA,* 1993, 90, 9730
	CCJ	McCall, T.B. et al., in *Biochem. Biophys. Res. Commun.* 1992,186, 680
	CCK	Meki AR, Mohey El-Dean ZM. *Serum interleukin-lbeta, interleukin-6, nitric oxide and alphal-antitrypsin in scorpion envenomed children.* Toxicon 1998 Dec;36(12):1851-9
	CCL	Molle W. et al. in *J Immunol* 1997, 159, 3555
	CCM	Morel, J. B. and Dangle, J.L., *Cell Death Differ* 1997, 4, 67 1; Beal, M. F., *Curr Opin Neurobiol* 1996, 6, 661
	CCN	Nathan, C. in *FASEB J.* 1992, 6, 3051
X	CCO	Novradovsky A, Brantly ML, Waclawiw MA, Chaudhary PP, Ihara H, Qi L, Tony Eissa N, Barnes PM, Gabriele KM, Ehrmantraut ME, Rogliani P, Moss J. *Endothelial Nitric Oxide Synthase as a Potential Susceptibility Gene in the Pathogenesis of Emphysema in alphal-Antitrypsin Deficiency. Am J Respir Cell Mol Biol* 1999 Mar 1;20(3):441-447
	CCP	Ooka T, Hatano Y, Yamamoto M, Ogawa K, Saika S. *Protective effects of human urinary trypsin inhibitor against trypsin-induced relaxation in rat aorta. Crit Care Med* 1996 Nov;24(11):1903-7
	CCQ	Patel R.P., et al. in *Biochim Biophys Acta* 1999,1411,385-400
	CCR	Patel T, Gores GJ, Kaufmann SH. *The role of proteases during apoptosis. FASEB J* 1996 Apr;10(5):587-97
X	CCS	Pellegrini A, Thomas U, Franchini M, Stockli M, Klauser S, Hunziker P, von Fellenberg R. *Identification of an aprotinin antiviral domain.* FEBS Lett 1994 May 16;344(2-3):261-5
X	CCT	~~Popko B. and Baerwald, K. D. in *Neurochem Res* 1999, 24, 33~~ 1
	CCU	Premack, B. A. and Schall, T. J., "*Chemokine Receptors: Gateways to Inflammation and Infection*", Nature Medicine, 2, 1174-1178 (1996)
	CCV	Pryor WA, Dooley MM, Church DF. *Mechanisms of cigarette smoke toxicity: the inactivation of human alpha-l-proteinase inhibitor by nitric oxide/isoprene mixtures in air.* Chem Biol Interact 1985 Jul;54(2):171-83
	CC W	Punjabi, C. J. et al., in *J. Immunol.* 1992, 149, 2179
	CCX	Rehman A, Whiteman M, Halliwell B. *Scavenging of hydroxyl radicals but not of peroxynitrite by inhibitors and substrates of nitric oxide syntheses.* Br J Pharmacol 1997 Dec; 122(8):1702-6

EXAMINER David Patton	DATE CONSIDERED 12/04/01

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

INFORMATION DISCLOSURE CITATION IN AN APPLICATION (PTO-1449)	ATTY. DOCKET NO. 114232.107	SERIAL NO. 09/518,098
	APPLICANT Leland SHAPIRO	
	FILING DATE May 3, 2000	GROUP 1653

		OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)
X	CCY	*Remington's Pharmaceutical Sciences* 1990, pp. 1519-1675, Gennaro, A. R., ed., Mack Publishing Company, Easton, PA.
X	CCZ	Sambrook, Fritsch & Maniatis, *Molecular Cloning: A Laboratory Manual, Second Edition* 1989, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
DR	CBA	Schini et al. in *Circ Res* 1994, 74, 24
DR	CBC	Sharpstone D, Rowbottom A, Nelson M, Gazzard B. *Faecal alpha I antitrypsin as a marker of gastrointestinal disease in HIV antibody positive individuals.* Gut 1996 Feb;38(2):206-10
DR	CBD	Shimizu T, Pommier Y. *DNA fragmentation induced by protease activation in p53-null human leukemia HL60 cells undergoing apoptosis following treatment with the topoisomerase I inhibitor camptothecin: cell-free system studies.* Exp Cell Res 1996 Aug 1;226(2):292-301
X	CBE	Sichko ZhV, Kozlova OL. *Experience in treating a herpetic infection with trypsin* [Article in Russian]. Vrach Delo 1991 Mar;(3):86-9
DR	CBF	Smith, M. E. in *Neurochem Res* 1999, *24*, 261
X	CBG	Szeghy G, Kenyeres B. *On the therapy of herpes simplex keratitis with heparin and trypsin.* [Article in German] Klin Monatsbl Augenheilkd 1968;153(6):827-30
X	CBH	Van Molle W, Libert C, Fiers W , Brouckaert P. *Alpha I-acid glycoprotein and alpha I-antitrypsin inhibit TNF-induced but not anti-Fas-induced apoptosis of hepatocytes in mice.* J Immunol 1997 Oct 1;159(7):3555-64
DR	CBI	Wood, E.R. et al. in *Biochem Biophys Res Commun* 1993,191, 767-74
X	CBJ	Zhirnov OP, Ovcharenko AV, Mel'nikova EE, Gaidamovich Sla, Bukrinskaia AG. *Antiviral activity of proteinase inhibitors in cultured cells infected with alpha-viruses.* Mol Gen Mikrobiol Virusol 1985 Dec;(12):30-6

EXAMINER	DATE CONSIDERED
David Lukton	12/4/01

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.